13F Filings History of Abingworth LLP

Latest 13F report
Q3 2025 - 07 Nov 2025
Signature - Title
John Heard - General Counsel
Location
London
Summary
This page shows a list of all the recent 13F filings made by Abingworth LLP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Abingworth LLP reported 18 stock holdings with total value $303,519,560 as of Q4 2022. Top holdings included PCVX, VRNA, VERA, HLVX, and ACET. Carlyle Group Inc. is reporting for Abingworth LLP.

Notify me when Abingworth LLP files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value

Carlyle Group Inc. is reporting for Abingworth LLP:

Name Holdings Value Location File Number
Carlyle Group Inc. $4,337,675,517 Washington, DC 028-15025
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q3 2025 $0 13F-NT 07 Nov 2025, 16:42
Q2 2025 $0 13F-NT 08 Aug 2025, 17:18
Q1 2025 $0 13F-NT 09 May 2025, 16:48
Q4 2024 $0 13F-NT 13 Feb 2025, 17:03
Q3 2024 $0 13F-NT 08 Nov 2024, 17:00
Q2 2024 $0 13F-NT 09 Aug 2024, 16:47
Q1 2024 $0 13F-NT 03 May 2024, 16:39
Q4 2023 $0 13F-NT 02 Feb 2024, 16:47
Q3 2023 $0 13F-NT 03 Nov 2023, 16:44
Q2 2023 $0 13F-NT 04 Aug 2023, 16:41
Q1 2023 $0 13F-NT 05 May 2023, 17:01
Q4 2022 18 $303,519,560 -$103,076,245 -$103,076,245 PCVX, VRNA, VERA, HLVX, ACET 13F-HR 10 Feb 2023, 15:28
Q3 2022 19 $292,475,000 +$4,920,015 +$4,920,015 PCVX, VERA, HLVX, ACET, VRNA 13F-HR 10 Nov 2022, 15:48
Q2 2022 21 $312,400,000 +$19,935,334 -$14,682,470 +$5,252,864 PCVX, SRRA, VERA, ACET, HLVX 13F-HR 15 Aug 2022, 06:30
Q1 2022 20 $352,495,000 +$18,868,079 +$18,868,079 PCVX, VERA, ACET, SRRA, JSPR 13F-HR 16 May 2022, 07:00
Q4 2021 20 $412,700,000 +$8,719,950 +$8,719,950 PCVX, VERA, JSPR, EFTR, ACET 13F-HR 16 Feb 2022, 10:26
Q3 2021 20 $440,666,000 +$126,001,466 -$1,729,030 +$124,272,436 PCVX, EFTR, JSPRXXXX, VERA, PHAT 13F-HR 15 Nov 2021, 06:05
Q2 2021 19 $323,501,000 +$56,702,886 $0 +$56,702,886 PCVX, PHAT, VERA, Spruce Bio, SIENXXXX 13F-HR 16 Aug 2021, 06:30
Q1 2021 17 $289,551,000 +$22,924,020 $0 +$22,924,020 PCVX, PHAT, Spruce Bio, ACET, VRNA 13F-HR 17 May 2021, 06:11
Q4 2020 15 $292,327,000 +$43,074,028 -$86,438 +$42,987,590 PCVX, Spruce Bio, PHAT, SLNO, VRNA 13F-HR 01 Mar 2021, 10:18
Q3 2020 17 $467,504,000 +$27,283,823 -$43,068,760 -$15,784,937 PCVX, PSNL, PHAT, SLNO, CRSP 13F-HR 16 Nov 2020, 05:15
Q2 2020 15 $354,662,000 +$138,889,712 +$138,889,712 PCVX, PSNL, PHAT, CRSP, SLNO 13F-HR 14 Aug 2020, 15:27
Q1 2020 16 $150,582,000 +$9,086,700 +$9,086,700 PSNL, PHAT, CRSP, SLNO, XCUR 13F-HR 14 May 2020, 06:05
Q4 2019 16 $206,909,000 +$48,927,800 -$6,650,247 +$42,277,553 PSNL, PHAT, CRSP, SIENXXXX, SLNO 13F-HR 14 Feb 2020, 05:05
Q3 2019 14 $158,151,000 +$15,750,000 -$23,951,032 -$8,201,032 PSNL, CRSP, XCUR, SIENXXXX, SLNO 13F-HR 14 Nov 2019, 05:06
Q2 2019 13 $260,678,000 +$147,947,787 -$12,563,614 +$135,384,173 PSNL, CRSP, SIENXXXX, AVDR, SLNO 13F-HR 14 Aug 2019, 06:09
Q1 2019 14 $111,733,000 +$13,401,116 -$4,606,291 +$8,794,825 CRSP, SIENXXXX, CHMA, SLNO, AVDR 13F-HR 15 May 2019, 06:15
Q4 2018 16 $110,057,000 +$7,983,988 -$3,002,899 +$4,981,089 CRSP, SIENXXXX, VRNA, SLNO, CHMA 13F-HR 14 Feb 2019, 05:16
Q3 2018 16 $168,201,000 +$11,274,017 -$6,721,734 +$4,552,283 CRSP, SIENXXXX, VRNA, PRTK, OBSVF 13F-HR 14 Nov 2018, 05:15
Q2 2018 16 $175,043,000 +$7,216,580 -$38,194,000 -$30,977,420 CRSP, SIENXXXX, PRTK, OBSVF, GTXI 13F-HR 14 Aug 2018, 07:00
Q1 2018 16 $160,870,000 +$2,975,990 -$14,280,483 -$11,304,493 CRSP, SIENXXXX, PRTK, GTXI, OBSVF 13F-HR 15 May 2018, 06:08
Q4 2017 17 $138,016,000 -$4,122,152 -$4,122,152 CRSP, SIENXXXX, PRTK, CBAY, OBSVF 13F-HR 14 Feb 2018, 05:10
Q3 2017 18 $144,439,000 +$8,612,012 -$15,396,464 -$6,784,452 CRSP, SIENXXXX, PRTK, CBAY, CHMA 13F-HR 14 Nov 2017, 05:13
Q2 2017 16 $125,658,000 -$2,526,237 -$2,526,237 CRSP, PRTK, SIENXXXX, CBAY, CASC 13F-HR 14 Aug 2017, 06:02
Q1 2017 17 $134,219,000 +$6,724,202 -$925,958 +$5,798,244 CRSP, PRTK, SIENXXXX, CBAY, CASC 13F-HR 15 May 2017, 07:36
Q4 2016 16 $118,457,000 +$53,189,436 -$1,763,242 +$51,426,194 CRSP, PRTK, SIENXXXX, NOVNXXXX, CHMA 13F-HR 14 Feb 2017, 05:04
Q3 2016 20 $104,334,000 +$4,796,392 -$232,440 +$4,563,952 SIENXXXX, PRTO, PRTK, CEMP, CHMA 13F-HR 14 Nov 2016, 06:20
Q2 2016 20 $95,498,000 +$4,784,632 +$4,784,632 PRTK, PRTO, SIENXXXX, TBRA, CEMP 13F-HR 12 Aug 2016, 06:03
Q1 2016 19 $107,619,000 +$256,002 +$256,002 PRTK, CHMA, PRTO, SIENXXXX, CEMP 13F-HR 13 May 2016, 06:16
Q4 2015 18 $165,700,000 +$6,113,000 -$248,997 +$5,864,003 CHMA, PRTO, PRTK, SIENXXXX, CEMP 13F-HR 16 Feb 2016, 06:22
Q3 2015 17 $171,209,000 +$46,093,020 -$1,252,359 +$44,840,661 CHMA, PRTO, PRTK, SIENXXXX, EVAR 13F-HR 13 Nov 2015, 05:49
Q2 2015 15 $216,417,000 +$18,975,369 -$3,652,243 +$15,323,126 SIENXXXX, PRTO, PRTK, AMRN, EVAR 13F-HR 14 Aug 2015, 06:47
Q1 2015 17 $235,176,000 +$1,024,001 -$40,647,121 -$39,623,120 SIENXXXX, PRTK, SUPN, DRNA, PRTO 13F-HR 14 May 2015, 06:03
Q4 2014 16 $352,088,000 +$108,002,692 +$108,002,692 RNA, PRTK, SIENXXXX, PTLA, SUPN 13F-HR 13 Feb 2015, 05:12
Q3 2014 13 $167,253,000 +$25,702,962 -$14,105,306 +$11,597,656 RNA, EVAR, SUPN, PTLA, DRNA Restatement 25 Nov 2014, 14:07
Q2 2014 12 $215,201,000 +$1,581,018 +$1,581,018 RNA, SUPN, PTLA, DRNA, AMRN 13F-HR 14 Aug 2014, 06:53
Q1 2014 13 $181,248,000 +$36,257,054 +$36,257,054 RNA, DRNA, SUPN, PTLA, AMRN 13F-HR 20 May 2014, 18:33
Q4 2013 11 $132,698,000 $0 PTLA, RNA, SUPN, AMRN, CEMP 13F-HR 14 Feb 2014, 07:47